Lupin, Glenmark Shift Focus To Inhalation And Nasal Covid-19 Drugs

After injectables and oral solid drugs, pharmaceutical companies are focusing on coming up with re-purposed inhalation products for Covid-19.

While Lupin is working on a remdesivir powder for inhalation, Glenmark has tied up with a Canadian Biotech firm for nitric oxide nasal spray that reduces Sars-CoV-2 viral load and thus transmission.

Remdesivir, an antiviral drug developed by American drug major Gilead for Ebola, was repurposed for Covid-19. The drug was in such demand during the first and second waves of the pandemic that massive shortages and spiralling black-market prices were reported.

Mumbai-based drug major Lupin has now got approval from the subject expert committee (SEC) advising the drugs regulator to conduct Phase 2 clinical trials for remdesivir powder inhalation. Lupin had presented a proposal to conduct Phase 2 and 3 studies for remdesivir powder for inhalation before the SEC.

Lupin did not respond to the queries sent.

The inhaled version of remdesivir, which is now available only in intravenous injectable form, could be cheaper. Remdesivir roughly costs from Rs 800-1,000 a vial to Rs 3,500 a vial varying across brands. Each patient needs at least six vials for a full course. Moreover, a dry powder inhaler would also deliver the drug directly into the lungs, the affected organ.

Meanwhile, another Mumbai-based firm Glenmark has tied up with Canadian biotech firm SaNOtize to manufacture, market, and distribute its nitric oxide nasal spray (NONS) for Covid-19 treatment in India and other Asian markets.

The SEC has allowed Glenmark to start Phase 3 trials of the product with conditions that anyone vaccinated with Covid-19 should be excluded from the disease.

A Glenmark spokesperson said NONS is designed to kill coronavirus in the upper airways, preventing it from incubating and spreading to the lungs. “It is based on Nitric Oxide, a natural nanom­olecule with proven anti-micr­obial properties, and which has a direct effect on SARS-CoV-2, the virus causing Covid,” the spokesperson said.

In March 2021, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment that significantly reduced viral load in Covid-19 patients and reduced the severity of symptoms.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor